PMV Pharmaceuticals Inc
PMVP1.380USD
-0.020-1.43%
交易中 （美东）报价延迟15分钟
71.70M总市值
亏损市盈率 TTM
关于 PMV Pharmaceuticals Inc 公司
PMV Pharmaceuticals, Inc. 是一家精准肿瘤学公司，致力于发现和开发针对 p53 的小分子、肿瘤无关疗法。p53 是一种肿瘤抑制蛋白，被称为基因组的守护者，正常或野生型 p53 具有消灭癌细胞的能力。该公司正在利用其精准肿瘤学平台开发一系列口服、有效且高度选择性的小分子候选产品，以 p53 突变或其他 p53 相关癌症为目标。其主要候选产品 PC14586 (rezatapopt) 是一种口服小分子，旨在有效且有选择性地纠正由特定 p53 突变 Y220C 引起的 p53 错误折叠，同时保留野生型 p53。在临床前研究中，PC14586 表现出选择性靶向活性，它在具有 p53 Y220C 突变的细胞中发挥作用，并表现出强大的抗肿瘤活性，表现为作为单一药物的强效肿瘤生长抑制和强效肿瘤消退。
公司简介
公司代码PMVP
公司名称PMV Pharmaceuticals Inc
上市日期Sep 25, 2020
CEODr. David H. Mack, Ph.D.
员工数量63
证券类型Ordinary Share
年结日Sep 25
公司地址400 Alexander Park Drive
城市PRINCETON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编08540
电话16096426670
网址https://www.pmvpharma.com/
公司代码PMVP
上市日期Sep 25, 2020
CEODr. David H. Mack, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Arnold J. Levine
Dr. Arnold J. Levine
Director
Director
409.84K
--
Ms. Deepika Jalota, Pharm.D.
Ms. Deepika Jalota, Pharm.D.
Chief Development Officer
Chief Development Officer
89.96K
-26.88%
Mr. Michael Carulli
Mr. Michael Carulli
Chief Financial Officer
Chief Financial Officer
60.15K
-31.96%
Mr. Robert Ticktin
Mr. Robert Ticktin
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Ms. Kirsten Flowers
Ms. Kirsten Flowers
Independent Director
Independent Director
--
--
Dr. Charles M. Baum, M.D., Ph.D.
Dr. Charles M. Baum, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. David H. Mack, Ph.D.
Dr. David H. Mack, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Independent Director
Independent Director
--
--
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Laurie D. Stelzer, CPA
Ms. Laurie D. Stelzer, CPA
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Arnold J. Levine
Dr. Arnold J. Levine
Director
Director
409.84K
--
Ms. Deepika Jalota, Pharm.D.
Ms. Deepika Jalota, Pharm.D.
Chief Development Officer
Chief Development Officer
89.96K
-26.88%
Mr. Michael Carulli
Mr. Michael Carulli
Chief Financial Officer
Chief Financial Officer
60.15K
-31.96%
Mr. Robert Ticktin
Mr. Robert Ticktin
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Ms. Kirsten Flowers
Ms. Kirsten Flowers
Independent Director
Independent Director
--
--
Dr. Charles M. Baum, M.D., Ph.D.
Dr. Charles M. Baum, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
OrbiMed Advisors, LLC
12.46%
BML Capital Management LLC
7.21%
Sio Capital Management, LLC
7.19%
ArrowMark Colorado Holdings, LLC
6.37%
PFM Health Sciences, LP
6.36%
Other
60.41%
持股股东
持股股东
占比
OrbiMed Advisors, LLC
12.46%
BML Capital Management LLC
7.21%
Sio Capital Management, LLC
7.19%
ArrowMark Colorado Holdings, LLC
6.37%
PFM Health Sciences, LP
6.36%
Other
60.41%
股东类型
持股股东
占比
Investment Advisor
23.22%
Investment Advisor/Hedge Fund
19.13%
Hedge Fund
18.26%
Private Equity
12.46%
Individual Investor
2.95%
Research Firm
0.25%
Bank and Trust
0.02%
Other
23.71%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
237
42.34M
81.49%
-24.79M
2025Q1
264
41.96M
80.78%
-26.31M
2024Q4
284
43.03M
82.89%
-24.24M
2024Q3
301
44.89M
87.58%
-26.76M
2024Q2
308
46.52M
90.86%
-26.11M
2024Q1
303
48.96M
95.71%
-22.51M
2023Q4
297
52.39M
102.89%
-12.57M
2023Q3
288
57.46M
118.56%
-6.14M
2023Q2
288
54.90M
119.94%
-8.05M
2023Q1
285
54.85M
119.84%
-9.91M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
OrbiMed Advisors, LLC
6.48M
12.46%
--
--
Mar 31, 2025
BML Capital Management LLC
3.75M
7.21%
+280.93K
+8.10%
Mar 31, 2025
Sio Capital Management, LLC
3.74M
7.19%
+163.23K
+4.57%
Mar 31, 2025
ArrowMark Colorado Holdings, LLC
3.31M
6.37%
-199.77K
-5.69%
Mar 31, 2025
PFM Health Sciences, LP
3.30M
6.36%
+703.12K
+27.06%
Mar 31, 2025
Euclidean Capital, L.L.C.
2.63M
5.06%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.18M
4.19%
+31.96K
+1.49%
Mar 31, 2025
Acadian Asset Management LLC
2.05M
3.94%
-31.69K
-1.52%
Mar 31, 2025
Alkeon Capital Management LLC
1.96M
3.78%
-1.36K
-0.07%
Mar 31, 2025
D. E. Shaw & Co., L.P.
949.73K
1.83%
-74.56K
-7.28%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 3000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Dimensional US Core Equity 1 ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
iShares Russell 3000 ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Dimensional US Core Equity 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
